Tier 3 — preclinical

Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism

Rafael Deminice, Robin P da Silva, Simon G Lamarre, Karen B Kelly, René L Jacobs, Margaret E Brosnan, John T Brosnan
Amino acids 2015 47(4):839-846

Bibliography

PubMed
PMID 25577261
DOI
10.1007/s00726-014-1913-x
Funding
Indexed grant support: Canadian Institutes of Health Research — Canada. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignExperimental animal and/or laboratory research
ModelHigh-fat-fed rats
SampleExperiment-specific biological replicates and model groups; see original methods
InterventionBetaine added to the experimental diet
Duration3 weeks
EndpointsLiver fat; One-carbon metabolism

What the study showed, in plain terms

Published in 2015, this source examined preclinical aging, brain and metabolic mechanisms. Design: Experimental animal and/or laboratory research. Sample/model: Experiment-specific biological replicates and model groups; see original methods. The exposure or intervention was Betaine added to the experimental diet. Follow-up or treatment period: 3 weeks.

Betaine reduced diet-induced liver-fat accumulation and altered SAM-related one-carbon metabolism in rats.

Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • Betaine reduced diet-induced liver-fat accumulation and altered SAM-related one-carbon metabolism in rats.
  • The recorded outcome domains were Liver fat; One-carbon metabolism.
  • The result applies to the tested exposure: Betaine added to the experimental diet; 3 weeks.

What this study can and cannot tell us

  • Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
Manal F Abdelmalek et al. · Hepatology (Baltimore, Md.) · 2009
Tier 2
Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
Andrew S Lim et al. · Hepatology (Baltimore, Md.) · 2026
Tier 4
Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential
Tatjana Radosavljevic et al. · Antioxidants (Basel, Switzerland) · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 3
Systematic profiling reveals betaine as an exercise mimetic for geroprotection
Lingling Geng et al. · Cell · 2025
Tier 4
Betaine and aging: A narrative review of findings, possible mechanisms, research perspectives, and practical recommendations
Emilia Zawieja et al. · Ageing research reviews · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology